Contraceptive Drugs

Contraceptive Drugs Market Outlook

The global contraceptive drugs market is projected to reach approximately USD 29 billion by 2035, growing at a compound annual growth rate (CAGR) of around 6.5% during the forecast period from 2025 to 2035. This growth is primarily driven by rising awareness regarding family planning and reproductive health, increasing access to contraceptive options, and the growing incidence of unplanned pregnancies. Additionally, advancements in contraceptive technologies and the expanding portfolio of drug types are expected to further boost market growth. The increasing acceptance of contraceptives among various demographics, including adolescents and young adults, is also a significant contributor to market expansion. Furthermore, government and non-governmental organizations are implementing various educational programs to promote contraceptive use, which is likely to enhance market penetration and accessibility.

Growth Factor of the Market

One of the most significant growth factors for the contraceptive drugs market is the heightened awareness regarding sexual and reproductive health across various demographics. As societies evolve, there is an increasing emphasis on informed family planning, leading to a rise in contraceptive adoption. Additionally, technological advancements have paved the way for the development of innovative contraceptive methods that cater to diverse needs, thus attracting a wider audience. The integration of telehealth and digital platforms for contraceptive counseling and prescriptions is also making contraceptive options more accessible, particularly in remote areas. Moreover, the collaboration between pharmaceutical companies and healthcare providers is fostering the introduction of new products with improved efficacy and safety profiles. Lastly, governmental initiatives aimed at promoting reproductive health and reducing unplanned pregnancies are generating significant momentum within the market.

Key Highlights of the Market

• Growing global awareness regarding reproductive health and the importance of family planning.
• Introduction of innovative contraceptive technologies catering to diverse consumer needs.
• Increasing access to contraceptive options through online platforms and telehealth services.
• Government initiatives and educational programs enhancing contraceptive use in various demographics.
• Rising incidence of hormonal imbalances and menstrual disorders driving demand for specific contraceptive solutions.

By Product Type

Oral Contraceptives:

Oral contraceptives remain one of the most widely used forms of contraception globally. This category includes various pills that contain hormones, typically estrogen and progestin, which prevent ovulation. The convenience of daily use, coupled with the ability to control menstrual cycles and mitigate symptoms such as acne and hormonal imbalances, contributes to the popularity of oral contraceptives. The rising trend of self-medication and the availability of over-the-counter options have also facilitated increased accessibility, driving market growth. Furthermore, manufacturers are continually working on enhancing formulations that minimize side effects while maximizing efficacy, which is likely to sustain consumer interest and expand market share.

Injectable Contraceptives:

Injectable contraceptives provide a long-term solution for women seeking effective birth control without the daily commitment required by oral pills. These contraceptives typically involve administering hormones via injection every few months, making them appealing for women who prefer a hassle-free option. The growing awareness of the long-lasting effects of injectables, combined with their effectiveness in preventing unplanned pregnancies, has contributed to their increasing adoption. Moreover, innovations in delivery methods, such as the development of auto-injectors, are expected to enhance user convenience and satisfaction, further driving market growth within this segment.

Contraceptive Patches:

Contraceptive patches have gained traction as a convenient and user-friendly alternative to traditional forms of birth control. These patches release hormones transdermally, providing continuous contraception for a week at a time. The ease of use and the reduction in the likelihood of user error, commonly associated with pills, make patches an attractive option for many women. Furthermore, the growing trend toward personalized healthcare solutions is leading to innovations in patch formulations that offer both contraceptive and therapeutic benefits. The increasing acceptance of non-invasive contraceptive methods is likely to bolster the market for contraceptive patches significantly.

Intrauterine Devices:

Intrauterine devices (IUDs) represent a highly effective long-term contraceptive method, and their popularity is rising due to their high efficacy rates and convenience. IUDs can provide protection against pregnancy for several years with minimal maintenance, appealing to women who prefer a set-and-forget solution. The growing awareness of the benefits of IUDs, alongside the introduction of non-hormonal options, is driving demand within this segment. Education initiatives explaining the role of IUDs in family planning, including their safety and reversibility, are further contributing to increased adoption rates among women worldwide.

Implants:

Implants are another long-acting reversible contraceptive method that has gained popularity due to their effectiveness and convenience. A small rod is inserted under the skin, releasing hormones that prevent ovulation for up to three years. The minimal required interaction with healthcare providers compared to other methods makes implants an appealing option for women seeking long-term birth control. The growing trend towards less invasive procedures, along with increased awareness of implantable contraceptives, is expected to drive significant growth in this market segment. Additionally, ongoing research and development are likely to yield new formulations and delivery methods, enhancing the attractiveness of implants.

By Application

Birth Control:

Birth control remains the primary application for contraceptive drugs, with a significant portion of the market dedicated to various contraceptive methods aimed at preventing unplanned pregnancies. The increasing awareness of family planning and reproductive health, combined with the rising incidence of unplanned pregnancies, is driving demand for effective birth control options. Modern contraceptive methods provide women with greater autonomy over their reproductive choices, thereby expanding the market further. The growing trend towards holistic healthcare approaches that encompass reproductive health is also expected to positively impact this segment.

Hormonal Imbalance:

The management of hormonal imbalances through contraceptive drugs represents a crucial application area, particularly for women experiencing conditions such as polycystic ovary syndrome (PCOS) or endometriosis. Hormonal contraceptives can help regulate menstrual cycles and alleviate symptoms associated with hormonal disorders, thereby driving demand in this segment. With an increasing number of women seeking treatment for hormonal issues, the market for contraceptives aimed at addressing these concerns is likely to witness significant growth. Moreover, the growing understanding of the connection between hormonal health and overall well-being is contributing to the acceptance of hormonal contraceptives as a therapeutic option.

Acne Treatment:

Another significant application of contraceptive drugs is in the treatment of acne, particularly in women whose acne is associated with hormonal fluctuations. Certain hormonal contraceptives have been clinically proven to reduce acne lesions and improve skin condition. This dual-action approach of addressing both birth control and acne treatment is appealing to many women, driving demand in this segment. Additionally, as more women become aware of the benefits of hormonal contraceptives for skin health, the market for this application is expected to grow. The integration of this treatment into broader skincare regimens further enhances its attractiveness among consumers.

Menstrual Disorders:

Contraceptive drugs play a vital role in managing various menstrual disorders, including irregular periods, dysmenorrhea, and amenorrhea. Hormonal contraceptives are often prescribed to help regulate menstrual cycles and reduce associated symptoms. The growing prevalence of menstrual disorders, coupled with increasing awareness and acceptance of hormonal treatments, is expected to drive demand in this segment. Furthermore, ongoing research into the long-term effects of contraceptive use in managing menstrual disorders is likely to bolster the market as healthcare professionals increasingly recognize the benefits of these drugs.

Others:

The 'Others' category encompasses a range of applications where contraceptive drugs are utilized, including but not limited to perimenopausal symptoms management and hormone replacement therapy. As the understanding of reproductive health evolves, the use of contraceptives for broader therapeutic purposes is gaining attention. The rising trend of personalized medicine, where treatments are tailored to individual needs, is likely to drive innovation within this segment. Moreover, as healthcare providers continue to explore the multifaceted benefits of contraceptive drugs, the market for these alternative applications is projected to expand significantly.

By Distribution Channel

Hospitals & Clinics:

Hospitals and clinics serve as critical distribution channels for contraceptive drugs, particularly for long-acting reversible contraceptives such as IUDs and implants. Healthcare professionals play a vital role in counseling and administering these methods, ensuring patients receive appropriate care and follow-up. The increasing reliance on professional healthcare services for contraceptive advice and procedures is driving demand through this channel. Additionally, the integration of family planning services within hospitals and clinics is enhancing accessibility for patients, contributing to market growth in this segment.

Retail Pharmacies:

Retail pharmacies represent a significant distribution channel for contraceptive drugs, providing easy access to a variety of over-the-counter options, including oral contraceptives and contraceptive patches. The convenience of purchasing contraceptives from local pharmacies contributes to their widespread use. Furthermore, the growing trend of self-medication and consumer empowerment in making healthcare decisions is driving demand through this channel. Retail pharmacies are also conducting awareness campaigns and offering consultations, enhancing their role in promoting contraceptive use among consumers.

Online Stores:

The rise of e-commerce has transformed the distribution landscape for contraceptive drugs, with online stores providing an increasingly popular avenue for purchasing contraceptives. The convenience and privacy offered by online shopping appeal to many consumers, particularly those seeking discreet options. The COVID-19 pandemic accelerated the adoption of online healthcare services and telehealth consultations, further boosting the online sales of contraceptive drugs. As consumers continue to embrace digital channels for healthcare-related purchases, the online segment is expected to witness significant growth in the coming years.

Public Health Programs:

Public health programs play a crucial role in increasing access to contraceptive drugs, particularly in low-income and underserved populations. These programs often provide contraceptives at low or no cost, ensuring that financial barriers do not hinder access to family planning services. The collaboration between governmental and non-governmental organizations to promote reproductive health initiatives has significantly expanded the reach of contraceptive options, driving demand through this channel. Additionally, ongoing education and awareness campaigns associated with public health programs are likely to enhance the utilization of contraceptives, contributing to market growth.

Others:

The 'Others' category in distribution channels encompasses various alternative methods of obtaining contraceptive drugs, including non-traditional outlets such as community health centers and mobile clinics. These channels often focus on reaching populations that face challenges in accessing conventional healthcare services. Increased collaboration between healthcare providers and community organizations is enhancing the availability of contraceptives in these settings, thereby driving demand. As awareness of reproductive health continues to grow, these alternative channels are expected to gain importance in the market.

By Ingredient Type

Progesterone:

Progesterone-based contraceptives are widely utilized due to their effectiveness in preventing ovulation and regulating menstrual cycles. These contraceptives are commonly found in various formulations, including pills, injections, and implants. The increasing prevalence of conditions such as endometriosis and abnormal menstrual cycles is driving demand for progesterone-based products. As more women seek effective solutions for hormonal management and birth control, the market for progesterone contraceptives is expected to witness significant growth. Additionally, ongoing research into the benefits of progesterone in addressing specific reproductive health concerns is likely to contribute to market expansion.

Estrogen:

Estrogen plays a crucial role in many contraceptive formulations, particularly in combined oral contraceptives that include both estrogen and progestin. These products are popular due to their dual benefits of preventing pregnancy and regulating menstrual cycles. As awareness regarding the benefits of hormonal contraceptives grows, the demand for estrogen-based options is likely to increase. Furthermore, ongoing developments aimed at reducing side effects and enhancing the efficacy of estrogen-containing contraceptives are expected to bolster this segment of the market. The focus on personalized contraceptive solutions tailored to individual hormonal profiles is also driving innovation in this area.

Levonorgestrel:

Levonorgestrel is widely recognized for its use in emergency contraceptive pills and is also a component of many long-acting contraceptives such as IUDs. The effectiveness of levonorgestrel in preventing pregnancy after unprotected intercourse has made it a popular choice among consumers. The increasing awareness of emergency contraception options and the rising demand for post-coital contraceptive methods are driving growth in this segment. Additionally, ongoing campaigns aimed at destigmatizing emergency contraception are likely to enhance consumer acceptance and boost sales of levonorgestrel-based products.

Ethinyl Estradiol:

Ethinyl estradiol is a synthetic form of estrogen commonly utilized in combination contraceptive methods, particularly in oral pills. Its effectiveness in regulating menstrual cycles and preventing ovulation has made it a staple in hormonal contraceptive formulations. The increasing prevalence of hormonal disorders and the growing acceptance of contraceptives for non-contraceptive purposes, such as acne treatment, are contributing to the demand for ethinyl estradiol-based products. Ongoing research focusing on optimizing formulations to improve safety and efficacy is expected to drive market growth within this segment.

Others:

The 'Others' category encompasses various alternative ingredient types used in contraceptive formulations. This includes innovative compounds and newer formulations that aim to enhance contraceptive efficacy while minimizing side effects. The ongoing research on non-hormonal contraceptives is also gaining traction, driven by a demand for options that reduce hormone-related side effects. As the market continues to evolve with advancements in pharmaceutical technologies, the acceptance of diverse ingredient types is expected to expand, contributing to overall market growth.

By Region

The North American contraceptive drugs market is projected to witness substantial growth, driven by the high prevalence of contraceptive use and the increasing demand for innovative contraceptive products. The market is expected to reach approximately USD 12 billion by 2035, with a CAGR of 6.8% during the forecast period. Factors such as comprehensive healthcare systems, high disposable incomes, and strong advocacy for reproductive health are contributing to the robust market landscape in this region. Furthermore, ongoing education and awareness programs aimed at promoting contraceptive use among adolescents and young adults are expected to enhance market penetration.

In Europe, the contraceptive drugs market is anticipated to grow significantly, with projections indicating a market size of around USD 9 billion by 2035. The growth is primarily fueled by rising awareness of reproductive health issues, increased access to contraceptive options, and the growing acceptance of hormonal contraceptives for therapeutic purposes. Additionally, the regulatory framework in Europe facilitates the introduction of new products, further enhancing market dynamics. The aging population in Europe is also expected to drive demand for contraceptive solutions tailored to the needs of older women, contributing to the overall growth of the market.

Opportunities

The contraceptive drugs market presents numerous opportunities for growth, particularly through the introduction of innovative products and the expansion of distribution channels. With the increasing awareness of reproductive health and family planning, there is a growing demand for diverse contraceptive options that cater to varying consumer preferences. Companies that invest in research and development to create new formulations, such as non-hormonal contraceptives or male contraceptive methods, stand to capture significant market share. Additionally, the rising trend of telemedicine and online healthcare services presents an opportunity for companies to reach consumers more effectively, making contraceptives more accessible, especially in rural areas where traditional healthcare facilities may be limited.

Moreover, partnerships between pharmaceutical companies, healthcare providers, and non-governmental organizations can enhance educational initiatives aimed at promoting contraceptive use. By addressing misconceptions and providing accurate information, these collaborations can significantly increase acceptance and utilization rates. Furthermore, expanding into emerging markets where access to contraceptives is limited provides significant opportunities for growth. As awareness and acceptance of family planning increase in these regions, companies that establish a presence early can benefit from first-mover advantages and capture a loyal consumer base.

Threats

Despite the promising growth prospects, the contraceptive drugs market faces several threats that could hinder its expansion. One of the primary threats is the increasing competition from alternative contraceptive methods, such as natural family planning and fertility awareness apps. As consumers become more informed and empowered in their reproductive choices, some may opt for non-pharmaceutical options, impacting the demand for traditional contraceptive drugs. Additionally, regulatory challenges and stringent approval processes for new contraceptive products can slow down innovation and market entry. Companies must navigate a complex landscape of regulations across different countries, which can pose significant hurdles for product development and distribution.

Another prominent threat is the growing concern regarding the side effects associated with hormonal contraceptives. Reports of adverse effects, both real and perceived, can deter consumers from using these products, leading to decreased market demand. Additionally, misinformation surrounding contraceptive safety can contribute to hesitance among potential users. Public backlash against hormonal contraceptives, fueled by social media and activist movements, can further exacerbate these issues. Consequently, it is crucial for manufacturers to engage in transparent communication and provide comprehensive information regarding the safety and benefits of their products to mitigate these threats.

Competitor Outlook

• Pfizer, Inc.
• Bayer AG
• Johnson & Johnson
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• HRA Pharma
• Amgen Inc.
• Allergan plc
• AbbVie Inc.
• Gedeon Richter Plc
• Watson Pharmaceuticals, Inc.
• Saint Pierre Pharmaceutique
• UCB S.A.
• Novartis International AG
• Ferring Pharmaceuticals

The competitive landscape of the contraceptive drugs market is characterized by a mix of established pharmaceutical giants and emerging players striving to capture market share. Major companies such as Pfizer, Bayer, and Merck are continuously innovating to develop new contraceptive products that cater to evolving consumer needs. These companies invest heavily in research and development to enhance their product portfolios and maintain a competitive edge. Additionally, strategic partnerships and collaborations with healthcare providers and organizations are prevalent, allowing these companies to expand their reach and improve market penetration. The commitment to addressing unmet needs within the contraceptive space is driving intense competition among these key players.

For instance, Pfizer has made significant strides in the contraceptive market through its innovative product line and extensive distribution network. The company's commitment to public health initiatives and partnerships with healthcare professionals has allowed it to establish a strong foothold in the market. Similarly, Bayer has focused on developing a diverse range of contraceptive methods, including hormonal and non-hormonal options, to cater to a wide audience. The company's marketing strategies emphasize reproductive health education, aiming to empower consumers and increase awareness about available contraceptive options.

Moreover, Merck's ongoing efforts in the contraceptive sector include expanding access to their products through various channels, including online pharmacies and community health programs. The company is dedicated to providing comprehensive reproductive healthcare solutions while addressing the unique needs of different demographics. Emerging players in the market, such as HRA Pharma and Amgen, are also making waves by introducing innovative contraceptive solutions that emphasize convenience and efficacy. As the market evolves and competition intensifies, these companies will continue to shape the contraceptive drugs landscape, driving advancements in product offerings and ensuring that consumers have access to a broad range of contraceptive options.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 UCB S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Amgen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 HRA Pharma
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AbbVie Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Pfizer, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gedeon Richter Plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Ferring Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Novartis International AG
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Saint Pierre Pharmaceutique
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Watson Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Contraceptive Drugs Market, By Application
    • 6.1.1 Birth Control
    • 6.1.2 Hormonal Imbalance
    • 6.1.3 Acne Treatment
    • 6.1.4 Menstrual Disorders
    • 6.1.5 Others
  • 6.2 Contraceptive Drugs Market, By Product Type
    • 6.2.1 Oral Contraceptives
    • 6.2.2 Injectable Contraceptives
    • 6.2.3 Contraceptive Patches
    • 6.2.4 Intrauterine Devices
    • 6.2.5 Implants
  • 6.3 Contraceptive Drugs Market, By Ingredient Type
    • 6.3.1 Progesterone
    • 6.3.2 Estrogen
    • 6.3.3 Levonorgestrel
    • 6.3.4 Ethinyl estradiol
    • 6.3.5 Others
  • 6.4 Contraceptive Drugs Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Stores
    • 6.4.4 Public Health Programs
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Contraceptive Drugs Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Contraceptive Drugs market is categorized based on

By Product Type

• Oral Contraceptives
• Injectable Contraceptives
• Contraceptive Patches
• Intrauterine Devices
• Implants

By Application

• Birth Control
• Hormonal Imbalance
• Acne Treatment
• Menstrual Disorders
• Others

By Distribution Channel

• Hospitals & Clinics
• Retail Pharmacies
• Online Stores
• Public Health Programs
• Others

By Ingredient Type

• Progesterone
• Estrogen
• Levonorgestrel
• Ethinyl estradiol
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer, Inc.
• Bayer AG
• Johnson & Johnson
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• HRA Pharma
• Amgen Inc.
• Allergan plc
• AbbVie Inc.
• Gedeon Richter Plc
• Watson Pharmaceuticals, Inc.
• Saint Pierre Pharmaceutique
• UCB S.A.
• Novartis International AG
• Ferring Pharmaceuticals